Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (PCRX) reported record EXPAREL sales of $507 million for 2021, contributing to total revenues of $541.5 million, a 26% increase from 2020. The company achieved a GAAP net income of $42 million ($0.95 per share) but faced a GAAP net loss of $5.1 million in Q4 2021. Adjusted EBITDA for the year rose to $204 million. The acquisition of Flexion Therapeutics bolstered its non-opioid pain management portfolio. Looking ahead, Pacira refrained from providing 2022 revenue guidance due to ongoing COVID-19 impacts on elective surgeries.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and year-end financial results for December 31, 2021, on February 24, 2022, prior to market opening. A live conference call and webcast will follow at 8:30 a.m. ET, allowing participants to engage directly. Interested parties can access the event through the company’s investor webpage. Pacira focuses on non-opioid pain management solutions and has three commercial products: EXPAREL, ZILRETTA, and iovera, aimed at reducing opioid dependency in pain treatment.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net product sales for EXPAREL and iovera° for January 2022. EXPAREL's net sales reached $36.3 million, a 4% increase from January 2021, with average daily sales at 104% of the previous year. Iovera° sales remained steady at $1.1 million. CEO Dave Stack reported growth trends for EXPAREL and the ongoing launch of the next-generation iovera° device. However, the company did not provide 2022 financial guidance due to ongoing uncertainty surrounding COVID-19's impact on elective surgeries.
Pacira BioSciences (Nasdaq: PCRX) reported record net product sales of $506.5 million for 2021, marking a 25.8% increase from 2020. Fourth quarter sales of EXPAREL reached $139.9 million, driven by strong growth, although affected by COVID-19-related restrictions in December. The company also recognized sales of ZILRETTA and iovera°, contributing to total revenue of $540.7 million to $541.7 million for the year. Despite challenges posed by the pandemic, Pacira remains optimistic about future growth in non-opioid pain management solutions.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 PM ET. Interested parties can access the live audio via the company's website, with a replay available for two weeks post-event. Pacira is dedicated to providing non-opioid pain management solutions and has three commercial-stage products: EXPAREL®, ZILRETTA®, and ioveraº®. Their mission focuses on reducing reliance on opioids and developing innovative treatments for chronic pain and related conditions.
Pacira BioSciences (Nasdaq: PCRX) has successfully closed a $375 million Senior Secured Term Loan B Facility, enhancing its operational and financial flexibility. The proceeds will be utilized for general corporate purposes, including replenishing funds from the recent acquisition of Flexion Therapeutics and repaying existing convertible senior notes. CFO Charles Reinhart emphasizes confidence in the company's forecasted earnings and operating cash flow, supporting their five-year growth plan aimed at revenue and earnings expansion.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales for November 2021, reporting EXPAREL sales of $46.5 million, a 22% increase from $38.1 million in November 2020. Average daily sales for EXPAREL reached 122% of the previous year. Iovera° reported $1.5 million in sales, up from $0.8 million. The company expects ZILRETTA sales to improve in 2022 following the acquisition of Flexion Therapeutics. Despite these growth trends, uncertainties related to the COVID-19 pandemic and the elective surgery market persist, leading to no financial guidance for 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, at 9:30 AM ET. Investors can access the live audio on the company's website under the 'Events' section. A replay will be available for two weeks after the event. Pacira focuses on providing non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at managing pain and reducing opioid reliance.
Pacira BioSciences has completed its acquisition of Flexion Therapeutics, enhancing its offerings in non-opioid pain management. This strategic move incorporates ZILRETTA, a patented treatment for osteoarthritis knee pain, into Pacira's portfolio, allowing earlier intervention for patients. The acquisition is expected to diversify revenue streams and enhance cash flows substantially. CEO David Stack emphasized the significance of this deal in evolving pain management and reducing opioid reliance.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 11:20 AM GMT. Live audio of the event can be accessed through the company’s website, with a replay available for two weeks after. Pacira is a leader in non-opioid pain management solutions, highlighted by its long-acting local analgesic, EXPAREL, launched in April 2012. The company aims to reduce opioid reliance through innovative therapies and technologies.